While CXCR4-targeted radionuclide therapies such as 177Lu/90Y Pentixather have shown promise in hematological malignancies [37,48], bone marrow toxicity remains a limitation in solid tumors due to high radiotracer uptake. This evidence concerns the gene CXCR4 and hematologic disorder.